linjc16/ctgov huggingface dataset:
Grip Test in Ventilated ICU Patients

Study Overview
=================
Brief Summary
-----------------
ICU patients do experience extubation failure. Guidelines rarely include muscle strength criteria. Prior work indicates that grip strength is a reliable surrogate for muscle strength. The purpose of the study is to assess the success rate of mechanical ventilation weaning based on the grip test.

Official Title
-----------------
The Role of the Grip Test in the Evaluation of Extubation Success in ICU Patients.

Conditions
-----------------
Mechanically Ventilated ICU Patients

Intervention / Treatment
-----------------
* Procedure: grip test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mechanically ventilated ICU patients Exclusion Criteria: tracheotomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: grip test|Muscle strength measurement by hand-held dynamometer|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extubation success |  | 48 hours without reintubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ICU, muscle strength, mechanical ventilation, weaning
Retrospective Study for Recurrent Nasal Polyposis

Study Overview
=================
Brief Summary
-----------------
A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.

Detailed Description
-----------------
A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out. All available information about these patients will be retrieved from our department data base including full personal history, medical history and type of surgery performed with operative details.. Missed patients due to any reason will be excluded from the study during. Complete information about patients' symptoms, onset, progression, severity and duration of recurrence after surgery will be taken from our department data base. Associated factors will be evaluated from data base (asthma, allergy, smoking, Samter's triad, cystic fibrosis, fungal sinusitis, immune status, etc.).

Official Title
-----------------
Recurrent Nasal Polyposis; A Two Years Retrospective Comprehensive Overview

Conditions
-----------------
Nasal Polyps

Intervention / Treatment
-----------------
* Procedure: nasal polyp surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with recurrent nasal polypi will be include in our study regardless their age and sex. Exclusion Criteria: Exclusion criteria: Patients with nasal polyps due to underlying neoplasm will be excluded from our study. Also, those with fresh polyps or missed patients during follow up due to any reason are not candidates for our research.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: nasal polyp surgery|A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrent Nasal Polyposis | Aim of the work: To evaluate patients with recurrent nasal polypi operated at Otorhinolaryngology department at sohag university hospital | A Two Years Retrospective Comprehensive Overview |
Evaluation of Prostate Cancer Margins

Study Overview
=================
Brief Summary
-----------------
Pathological assessment of prostate tissue

Official Title
-----------------
Evaluation of Prostate Cancer Margins

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Other: Evaluation of prostate cancer margins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with prostate cancer Subject must be scheduled for robotic-assisted radical prostatectomy at the clinical site. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Evaluation of prostate cancer margins|Evaluation of prostate cancer margins|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive Margin | Detection of positive margin | Immediately postoperatively, expected same day as surgery |
Oxygen Wound Therapy Feasibility Study

Study Overview
=================
Brief Summary
-----------------
Determine the feasibility of using a new topical oxygen therapy device to treat hard to heal lower leg wounds.

Official Title
-----------------
Oxygen Wound Therapy Feasibility Study

Conditions
-----------------
Chronic Leg Ulcer

Intervention / Treatment
-----------------
* Device: Series Topical Oxygen Therapy
* Device: Paired Topical Oxygen Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hard to heal lower leg wounds as determined by the treating clinician. Patient has a wound area greater than the area of the interface Aged 16 years and over Able to provide informed consent Exclusion Criteria: Lower limb wounds with bone or tendon exposed Infected wounds which require treatment with antibiotics Wounds with critical bioburden requiring a medicated dressing Wounds that require dressing changes more than every second day, for example high exudating wounds Wounds with slough covering more than 30% of the wound surface

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Series<br>Standard wound care for 4 weeks followed by intervention device wound care for up to 12 weeks. | Device: Series Topical Oxygen Therapy<br>* Standard care provided to the whole wound followed by intervention device care to the whole wound.<br>|
| Active Comparator: Paired<br>Intervention device wound care to a portion of wound and standard wound care to the remaining portion of the wound, for up to 12 weeks. | Device: Paired Topical Oxygen Therapy<br>* Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in wound area | cm^2 | 12 weeks |
Spectral CT With Advanced CT Technology

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to collect data to evaluate feasibility of the using photon-counting CT in a clinical setting.

Detailed Description
-----------------
Data collected in this study includes an assessment of image quality parameters including spatial resolution, image contrast, and noise that will evaluate the product and how this photon-counting CT technology can be used to reduce the overall radiation dose in CT imaging, and enhance clinical applications for CT technology.

Official Title
-----------------
Spectral Computed Tomography With Photon-counting Detector

Conditions
-----------------
CT Photon-Counting

Intervention / Treatment
-----------------
* Device: CT with a photon-counting detector


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >50 years Male Normal renal function per standardized guidelines (GFR > 60 mL/min) Previous CT examination at KS no more than 12 months prior to the study examination Signed informed consent Exclusion Criteria: Iodine contrast is contraindicated.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Interventional Model Description: The single group model will enroll subjects from 5 anatomical areas (lungs, brain/carotid vessels, heart/chest, MSK and abdomen) where CT imaging is applicable and where data on the photon-counting CT is needed to assess feasibility and guide further development of the technology.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subject's Scanned with Investigational Device<br> | Device: CT with a photon-counting detector<br>* Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate feasibility of the photon-counting CT in a clinical setting. | The primary objective of this study is to collect and evaluate raw CT scan data collected using the photon-counting CT. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect feedback on performance and images generated on the photon-counting CT. | Gather feedback on the performance and image quality of the reconstructed images produced by using the photon-counting CT. | 1 year |
Estrogen and Graft Atherosclerosis Research Trial (EAGER)

Study Overview
=================
Brief Summary
-----------------
To determine if postmenopausal hormone replacement therapy in women following coronary bypass surgery would reduce the occurrence of graft occlusion and delay the development of graft atherosclerosis.

Detailed Description
-----------------
BACKGROUND: Coronary atherosclerosis is a major cause of death in women in the United States. Although coronary artery bypass surgery decreases symptomatic and clinical evidence of ischemia, it does not alter the underlying process. Patients may present several years later with recurrent symptoms that may be a result of occlusion of saphenous vein grafts, development of atherosclerotic disease in vein grafts, or progression of underlying disease. Any intervention that can reduce the rate of progression of coronary atherosclerosis following bypass surgery would provide significant benefit for women following bypass surgery and possibly for other women with atherosclerotic disease. Observational studies suggest that postmenopausal estrogen replacement therapy is associated with a reduction in cardiac morbidity. DESIGN NARRATIVE: The study was a randomized, double-blind, controlled trial. Subjects were randomized to conjugated estrogen with daily medroxyprogesterone or placebo within two weeks of bypass surgery. Graft occlusion and development of vein graft atherosclerosis were measured by comparing quantitative coronary angiographic and vascular ultrasonic assessment of disease severity and extent performed at six months and three and a half years after randomization. The primary outcome variables included the occurrence of graft occlusion at six months and the change in severity and extent of atherosclerosis in the saphenous vein grafts over three years. The trial determined the influence of hormone replacement therapy on the primary outcome variables. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Coronary Arteriosclerosis, Coronary Disease, Heart Diseases, Myocardial Ischemia, Postmenopause

Intervention / Treatment
-----------------
* Drug: hormone replacement therapy
* Drug: estrogens
* Drug: medroxyprogesterone


Participation Criteria
=================
Eligibility Criteria
-----------------
Postmenopausal women who had undergone coronary artery bypass graft.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: hormone replacement therapy|nan|
|Drug: estrogens|nan|
|Drug: medroxyprogesterone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of corticosteroids on the frequency and severity of Mylotarg® infusion-related adverse events, to evaluate the effect of corticosteroids on the efficacy of Mylotarg® induced complete response (CR) and complete response with incomplete platelet recovery (CRp) at one-month post treatment.

Official Title
-----------------
A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML)

Conditions
-----------------
Leukemia, Myelocytic, Acute, Infusions, Intravenous

Intervention / Treatment
-----------------
* Drug: Mylotarg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with CD33 positive, resistant or relapsed AML. Patients > 18 years of age. ECOG performance status 0-2. Exclusion Criteria: Fever (>38), chills or hypotension (systolic BP<105mmHg) in the 48 hours preceding therapy. Use of corticosteroids, diphenhydramine or acetaminophen within 24 hours of enrollment. Participation in any other Mylotarg® protocol.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Mylotarg|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of corticosteroids on the frequency and severity of Mylotarg® infusion-related adverse events. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of corticosteroids on the efficacy of Mylotarg® induced complete response (CR) and complete response with incomplete platelets recovery (CRp) at one-month post treatment. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Leukemia, Mylotarg, Safety, Adverse Events
Non Grafted Maxillary Sinus Floor Elevation With Implant Placement Versus the Use of Short Endosseous Implants

Study Overview
=================
Brief Summary
-----------------
Assessment the need for sinus floor elevation when restoring atrophic posterior maxilla or it will be enough to use of short implant

Official Title
-----------------
Non Grafted Maxillary Sinus Floor Elevation With Simultaneous Implant Placement Versus the Use of Short Endosseous Implants

Conditions
-----------------
Primary Stability of Implants, Marginal Bone Loss

Intervention / Treatment
-----------------
* Procedure: Non grafted maxillary sinus floor elevation with simultaneous implant placement
* Procedure: using short dental implants for posterior atrophic maxilla


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with partially edentulous in the posterior area of the maxilla, with a residual ridge that allowed insertion of ≤8 mm length implants. Both sexes. No intraoral soft and hard tissue pathology No systemic condition that contraindicate implant placement. Exclusion Criteria: Sinus pathology. Heavy smokers more than 20 cigarettes per day. Patients with systemic disease that may affect normal healing. Psychiatric problems Disorders to implant are related to history of radiation therapy to the head and neck neoplasia, or bone augmentation to implant site Immunodeficiency pathology, bruxism, stress situation (socially or professionally), emotional instability, and unrealistic aesthetic demands.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Non grafted maxillary sinus floor elevation with implant pacem<br> | Procedure: Non grafted maxillary sinus floor elevation with simultaneous implant placement<br>* lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure<br>|
| Experimental: using short dental implants for posterior atrophic maxilla<br> | Procedure: using short dental implants for posterior atrophic maxilla<br>* placement of short dental implant with bone height below 8mm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| primary stability | measuring primary stability using osstel | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| marginal bone loss | measuring marginal bone loss using cone beam ct | 6 months |
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C

Study Overview
=================
Brief Summary
-----------------
The primary objective of this sub-study, 2019-01B, is to collect blood specimens for research use in the development and validation of a blood-based test for colorectal cancer (CRC).

Detailed Description
-----------------
Subjects who consent to enroll in Exact Sciences Protocol 2019-01 BLUE-C, will be invited to participate in this sub-study. Subjects enrolled in the Exact Sciences Protocol 2019-01 BLUE-C, who provide written informed consent to participate in this sub-study, will have a blood sample collected at enrollment.

Official Title
-----------------
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Other: Blood Sample Collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is currently enrolled in Exact Sciences Protocol 2019-01 BLUE-C. Subject is willing and able to provide a blood sample. Subject is willing and able to sign informed consent. Exclusion Criteria: 1. Subject has any condition that in the opinion of the Investigator should preclude participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects Enrolled in 2019-01 BLUE-C<br>Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment. | Other: Blood Sample Collection<br>* Subjects participating in the study will have blood drawn at enrollment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood-based biomarkers associated with genetic and epigenetic alterations. |  | Point in time blood collection (1 day) at enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood Draw